BIO-TECHNE Corp Operating Lease Liability
BIO-TECHNE Corp (TECH) had Operating Lease Liability of $89.09 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-24
- 2026-06-30: Operating Lease, Liability $89.09M.
- 2026-03-31: Operating Lease, Liability $90.32M.
- 2025-12-31: Operating Lease, Liability $90.89M.
- 2025-09-30: Operating Lease, Liability $94.47M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $89.09M 10-K · filed 2026-08-24 |
| 2026-03-31 | $90.32M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $90.89M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $94.47M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $98.06M 10-K · filed 2026-08-24 |
| 2025-03-31 | $93.50M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $95.13M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $98.92M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $100.54M 10-K · filed 2025-08-22 |
| 2024-03-31 | $105.73M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $108.70M 10-Q · filed 2024-02-07 |
| 2023-09-30 | $109.53M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $104.97M 10-K · filed 2023-08-23 |
| 2023-03-31 | $103.99M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $89.16M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $76.87M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $70.06M 10-K · filed 2022-08-24 |
| 2022-03-31 | $68.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $69.53M 10-Q · filed 2022-02-07 |
| 2021-09-30 | $77.06M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $79.23M 10-K · filed 2021-08-25 |
| 2021-03-31 | $77.23M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $73.58M 10-Q · filed 2021-02-08 |
| 2020-09-30 | $75.39M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $76.78M 10-K · filed 2020-08-26 |
| 2020-03-31 | $79.03M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $81.09M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $82.13M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |